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OBJECTIVES The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous
Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-
Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI)
study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and
that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial
infarction (STEMI) who do not receive timely reperfusion.
BACKGROUND An optimal treatment strategy has not been identified for the many STEMI patients
ineligible for acute reperfusion.
METHODS A total of 1,224 patients were enrolled in 91 centers in 14 countries between July 1999 and
July 2002. Patients with STEMI ineligible for reperfusion were randomized to enoxaparin,
enoxaparin plus tirofiban, UFH, or UFH plus tirofiban. All patients received oral aspirin. The
primary efficacy end point was the 30-day combined incidence of death, reinfarction, or recurrent
angina; the primary analysis was the comparison of the pooled enoxaparin and UFH groups.
RESULTS The incidence of the primary efficacy end point was 15.7% enoxaparin versus 17.3% for UFH
(odds ratio 0.89 [95% confidence interval {CI} 0.66 to 1.21]) and 16.6% for tirofiban versus
16.4% for placebo (odds ratio 1.02 [95% CI 0.75 to 1.38]). The Thrombolysis In Myocardial
Infarction (TIMI) major hemorrhage rate was 1.5% for enoxaparin versus 1.3% for UFH
(odds ratio 1.16 [95% CI 0.44 to 3.02]) and 1.8% versus 1% for tirofiban versus placebo (odds
ratio 1.82 [95% CI 0.67 to 4.95]).
CONCLUSIONS This study did not show that enoxaparin significantly reduced the 30-day incidence of death,
reinfarction, and recurrent angina compared with UFH in non-reperfused STEMI patients.
However, enoxaparin appears to have a similar safety and efficacy profile to UFH and may be
an alternative treatment. Additional therapy with tirofiban did not appear beneficial. (J Am
Coll Cardiol 2003;42:1348–56) © 2003 by the American College of Cardiology Foundation
Approximately 750,000 people in the U.S. suffer an acute
myocardial infarction (MI) each year (1). For patients
presenting within 12 h of symptom onset, the standard of
care is prompt coronary reperfusion with either thrombol-
ysis or percutaneous coronary intervention (PCI) (2,3).
However, the majority still does not receive reperfusion-
therapy (4), owing to presentation later than 12 h after
See page 1357
symptom onset or to other clinical or circumstantial factors
(5,6). While extending the time window for reperfusion
sounds promising (7–10), to date, prospective randomized
trials have been unable to substantiate a benefit for such a
course of action. There remains, therefore, no consensus on
how to treat non-reperfused ST-segment elevation MI
(STEMI) patients who normally constitute a high-risk
group, with minimum 13% mortality at 30 days (11).
Antithrombotic therapy may be an alternative to late
reperfusion therapy, by enhancing endogenous thrombolysis
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with minimal risk to the patient. The low-molecular-weight
heparin (LMWH) enoxaparin has shown greater efficacy
than unfractionated heparin (UFH) in non–ST-segment
elevation acute coronary syndromes, albeit with an increased
risk of minor bleeding (12,13). As an adjunct to thrombol-
ysis in STEMI, greater or equivalent efficacy has been
observed with enoxaparin (14–16). Furthermore, compared
with standard therapy, adjunctive antiplatelet therapy with
glycoprotein IIb/IIIa antagonists in addition to UFH and
aspirin reduces the incidence of ischemic events in patients
with acute coronary syndromes (17–19). It is possible that
the combined use of LMWH and glycoprotein IIb/IIIa
antagonists may provide synergistic benefits, and combina-
tion therapy with enoxaparin and tirofiban has already been
shown to be safe in patients with acute coronary syndromes
(20,21).
We therefore established the Treatment with Enoxaparin
and Tirofiban in Acute Myocardial Infarction in patients
ineligible for reperfusion (TETAMI) study, a randomized
multicenter clinical trial to investigate the risks and benefits
of enoxaparin versus UFH, and the addition of tirofiban
versus placebo. Our hypothesis was that enoxaparin was
superior to UFH in non-reperfused STEMI patients, and
that the addition of tirofiban to the anticoagulant regimens
was better than that of placebo.
METHODS
Details of the study design (summarized in the following
text) have been published previously (22).
Patients. Male and non-pregnant female patients at least
18 years of age were enrolled in 91 study centers (listed at
the end of this report) in 14 countries between July 1999
and July 2002. Patients were considered for inclusion if they
presented with STEMI and were deemed unsuitable for
treatment with thrombolytics or primary PCI. All patients
gave informed consent. The protocol received ethics com-
mittee approval in all countries.
Patients with contraindications to any study drug were
excluded, as were those with cardiogenic shock, renal
insufficiency, thrombocytopenia, or a current treatment
antithrombotic regimen that included more than 24 h of
anticoagulation, or any glycoprotein IIb/IIIa antagonist.
Study design. The trial was a randomized, double-blind,
double-dummy, placebo-controlled, parallel group study.
Eligible patients were randomized to one of four treatment
regimens, according to a two-by-two factorial design (Fig.
1): 1) enoxaparin, 30-mg intravenous bolus, followed by
1mg/kg subcutaneously every 12 h; 2) enoxaparin, 30-mg
intravenous bolus, followed by 1mg/kg subcutaneously every
12 h, plus tirofiban, 10 g/kg intravenous bolus, followed by
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
CABG  coronary artery bypass grafting
CI  confidence interval
LMWH  low-molecular-weight heparin
MI  myocardial infarction
PCI  percutaneous coronary interventions
PTCA  percutaneous transluminal coronary
angioplasty
STEMI  ST-segment elevation myocardial infarction
TETAMI  Safety and Efficacy of Subcutaneous
Enoxaparin Versus Intravenous UFH With
and Without Tirofiban in the Treatment of
Acute Myocardial Infarction in patients
ineligible for reperfusion
UFH  unfractionated heparin
Figure 1. Disposition of patients. UFH  unfractionated heparin.
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continuous infusion (0.1 g/kg per min); 3) UFH, 70 U/kg
intravenous bolus followed by continuous infusion (15 U/kg
per h initially) adjusted according to activated partial throm-
boplastin time (aPTT); or 4) UFH, 70 U/kg intravenous
bolus followed by continuous infusion (15 U/kg per h)
adjusted to aPTT plus tirofiban, 10 g/kg intravenous
bolus, followed by continuous infusion (0.1 g/kg per min).
Treatment with UFH/enoxaparin was given for at least 2
and up to 8 days; tirofiban/placebo was given for between 2
days and 96 h (108 h if percutaneous transluminal coronary
angioplasty [PTCA] or stent placement was performed
between 84 and 96 h after acute MI). All patients also
received oral aspirin, 100 to 325 mg/day, for at least 30 days.
Dose selection. Dosing regimens for UFH and enoxaparin
were based on experience gained from the Thrombolysis In
Myocardial Infarction (TIMI) 11B (12) trial, and on a
post-hoc meta-analysis of the subgroup of Efficacy and
Safety of Subcutaneous Enoxaparin in Non–Q-wave Cor-
onary Events (ESSENCE) (13) and TIMI 11B patients
who were subsequently found to have Q-wave MI (n 
252). This analysis revealed a 28% reduction in the com-
posite incidence of death, MI, and recurrent angina at 30
days (23). Dosing regimens for tirofiban were based on
experience gained from the Randomized Efficacy Study of
Tirofiban for Outcomes and Restenosis (RESTORE) (24),
and the Platelet Receptor inhibition in Ischemic Syndrome
Management in Patients Limited by Unstable signs and
Symptoms (PRISM-PLUS) trials (17).
End points. All efficacy end points were adjudicated by an
independent clinical events committee blinded to the treat-
ment allocation. The primary efficacy parameter was the
incidence of the composite of all death, reinfarction, or
recurrent angina at 30 days. All end points were compared
for the pooled UFH and enoxaparin groups, as well as for
the pooled tirofiban and placebo groups. Secondary end
points were: 1) incidence of the composite triple end point
at 48 h and 8 days; 2) incidence of the composite double end
point of death and reinfarction at 48 h, 8 and 30 days; 3)
rates of cardiac catheterization, PTCA, or coronary artery
bypass grafting (CABG) at 30 days; and 4) all outcomes at
6-month follow-up.
Reinfarction was diagnosed on the basis of symptoms,
electrocardiogram, and cardiac enzymes. Reinfarction after
PCI was defined as creatine kinase of 3  the upper limit
of normal and 50% greater than the previous value or new
Q-waves in two or more contiguous leads. Recurrent angina
was defined as a single episode of angina at rest lasting at
least 20 min or at least two episodes lasting 10 min or more
within 24 h associated with new ST-segment changes,
invasive cardiac procedures, or rehospitalization for unstable
angina.
Safety parameters included the incidence of major hem-
orrhage, which was categorized according to the TIMI
criteria. Thrombolysis in Myocardial Infarction major
bleeding was defined as: 1) hemoglobin drop 5 g/dl (with
or without an identified site, not associated with CABG); 2)
intracranial hemorrhage; 3) cardiac tamponade. Thrombol-
ysis in Myocardial Infarction minor hemorrhage was de-
fined as: hemoglobin drop 3 g/dl but 5 g/dl, with an
identified bleeding site. Thrombolysis in Myocardial Infarc-
tion “loss no site” was hemoglobin drop3 g/dl but5 g/dl
without an identified bleeding site. As well as hemorrhage
and stroke, non-hemorrhagic adverse events and thrombo-
cytopenia were also recorded. Efficacy and safety end points
were assessed daily between randomization and day 8 or
until hospital discharge, and at follow-up visits or by
telephone contact at 30 days and 6 months.
Sample size and statistical analysis. The sample size was
calculated assuming a 25.5% overall event rate in UFH-
treated patients, and a 30% relative reduction in event rate
with enoxaparin versus UFH. Assuming a type I error rate
of 5%, a sample size of 450 patients in each treatment arm
would provide 80% power to demonstrate superiority of
enoxaparin over UFH. The planned, unblinded, sample size
reassessment, which was performed after recruitment of 439
patients, revealed a lower UFH event rate than expected. As
a result, the sample size was increased to a total of 1,224 to
maintain sufficient power to achieve the primary aim.
Primary efficacy analyses were performed on the
intention-to-treat population, which included all patients
randomized to treatment, irrespective of whether they
received study medication. In this population, patients were
analyzed in the treatment group they were randomized into.
The incidence of the composite triple end point at 30 days
was compared between treatment groups (enoxaparin versus
UFH; tirofiban vs. placebo) using a chi-square test after
checking that there was no interaction between enoxaparin/
UFH and tirofiban/placebo. Kaplan-Meier plots were made
of the “time-to-first-event,” and the log-rank test was used
to compare treatment groups. Other analyses of robustness
of the primary efficacy parameter and all safety analyses were
performed on the all-treated population, which included all
patients who received at least one dose of study medication
(patients analyzed in the treatment group they actually
received); chi-square test or only descriptive statistics were
used. Odds ratios and 95% confidence intervals (CI) were
also calculated for the main comparisons of enoxaparin
versus UFH and tirofiban versus placebo. All tests were
performed at a 5% alpha level. Statistical analyses were
performed using the Statistical Analysis System (SAS)
software package.
RESULTS
A total of 1,224 patients were enrolled into this study. Of
these, 1,216 received treatment (Fig. 1).
Baseline characteristics were similar across the four indi-
vidual groups (Table 1). The mean age was 63 years, the
majority of patients were males (72.4%), and most patients
were Caucasian (89.7%). None of the baseline characteris-
tics recorded was found to be significantly different between
treatment groups.
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All 1,224 patients underwent an electrocardiogram, and
results indicated ST-segment elevation in 86.8% of patients.
Q-wave MI was identified in 68.1% of patients, and
conduction abnormalities were present in 12.7% of patients
(Table 1). The reasons identified for not reperfusing these
patients with thrombolytic therapy were late arrival (79.4%),
no ST-segment elevation on admission (8.7%), major con-
traindication (1.4%), minor contraindication (2.6%), and
“other” (12.3%). Percutaneous coronary intervention was
not employed as a result of late arrival (65.8%), unavailabil-
ity of a cath lab (33.8%), PCI not done routinely (27.2%),
and “other” (7.1%). In patients arriving within the 12-h
window, the predominant reason for not giving a thrombo-
lytic or performing PCI was still late arrival (59.8% and
42.8%, respectively).
A summary of exposure to the study drugs is shown in
Table 2. It should be noted that 28.0% of all patients had
been given UFH just before the study, and, in total, 32.5%
were not administered the bolus dose of the study drugs.
The majority of patients received their first dose of study
medication more than 12 h after onset of symptoms
(80.4%), with 18.6% of patients receiving their first dose
between 4 to 12 h from symptom onset, and 1.0% of
patients receiving their first treatment dose 4 h after onset
of symptoms. The mean time to first dose from onset of
symptoms was 16.9 h for the enoxaparin groups and 17.5 h
for the UFH groups. Median duration of all treatments was
similar (range, 2.3 to 2.5 days).
A total of 126 patients (10.3%) prematurely discontinued
treatment, with the primary reasons being adverse events in
52 patients, death in 15 patients, and study end point in 21
patients. On completion of the study at 30 days, a total of
1,134 patients (92.6%) remained alive, 85 patients died
(6.9%), and five patients (0.4%) were lost to follow-up.
Efficacy. The incidence of the primary efficacy end point
(death, reinfarction, or recurrent angina at 30 days) was not
significantly different between the pooled enoxaparin and
UFH groups (15.7% and 17.3%, Table 3), and similar results
Table 1. Summary of Baseline Characteristics (Intention-to-Treat Population, N  1,224)
All
(N  1,224)
Enoxaparin/Placebo
(n  299)
Enoxaparin/Tirofiban
(n  305)
UFH/Placebo
(n  306)
UFH/Tirofiban
(n  314)
Baseline characteristics
Mean age (yrs) 62.8 62.4 62.9 62.5 63.2
Patients (%)
Male 72.4 72.2 75.4 71.6 70.4
Anterior MI 44.7 46.8 41.6 45.1 45.2
Killip class I 85.8 87.6 85.9 82.4 87.3
Killip class II 13.2 11.4 13.1 16.7 11.8
Killip class III 1.0 1.0 1.0 1.0 1.0
ECG characteristics
Any ST-segment elevation 86.8 83.9 90.2 86.9 86.0
Q-wave MI 68.1 70.2 69.5 66.3 66.6
Conduction abnormalities 12.7 13.4 10.5 13.7 13.1
ECG  electrocardiography; MI  myocardial infarction; UFH  unfractionated heparin.
Table 2. Summary of Exposure to Study Drugs (All Treated Population, N  1,216)
Patients (%)
All Patients
(N  1,216)
Enoxaparin/Placebo
(n  297)
Enoxaparin/Tirofiban
(n  303)
UFH/Placebo
(n  306)
UFH/Tirofiban
(n  310)
Enoxaparin/placebo bolus received 65.3 69.0 64.7 65.0 62.6
Reason for no bolus
Pretreated with UFH* 28.0 24.6 29.0 29.7 28.7
Other 6.7 6.4 6.3 5.2 8.7
UFH/placebo bolus received 61.2 64.3 62.0 60.8 57.7
Reason for no bolus
Pretreated with UFH* 32.5 29.6 32.0 34.0 34.2
Other 6.3 6.1 5.9 5.2 8.1
Tirofiban/placebo bolus received 100.0 100.0 100.0 100.0 100.0
SC dose and IV infusion dose exposure
Enoxaparin SC received 99.7 99.3
Median duration of enoxaparin SC treatment
(days)
2.4 2.3
UFH IV infusion received 100 100
Median duration of UFH IV infusion treatment
(days)
2.5 2.5
Tirofiban IV infusion received 99.7 99.7
Median duration of tirofiban IV infusion treatment
(days)
2.4 2.4
IV  intravenous; SC  subcutaneous; UFH  unfractionated heparin.
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were also observed for pooled placebo group versus tirofiban
group (Table 4). No statistically significant treatment interac-
tions were seen across the four individual treatment groups (p
 0.846, Table 5). No notable differences were seen in any of
the other parameters recorded (Tables 3 and 5), except for the
rate of PCI on treatment, which is highest in tirofiban-treated
patients (Table 5). Survival rates were similar across all four
treatment groups and between the pooled groups.
The total percentage of patients requiring at least one
revascularization at 30 days was 28.1%; 21.6% required at
least one PCI, and 6.6% required at least one CABG
(Tables 3 and 4), with only 2.2% of patients undergoing
PCI while on treatment with enoxaparin or UFH. There
were no differences between the groups with respect to these
procedures, and only three patients had an MI after a PCI
procedure (one on enoxaparin, two with UFH).
Time to first event for the composite triple end point in
the pooled enoxaparin and UFH groups is shown in Figure
2. Although the Kaplan-Meier curves separate by day 5, the
differences between the groups did not reach statistical
significance.
Safety. By 30 days, 17 patients suffered a TIMI major
hemorrhage 1.5% (9 patients) for enoxaparin versus 1.3% (8
patients) for UFH (odds ratio 1.16 [95% CI 0.44 to 3.02])
and 1.8% (11 patients) versus 1.0% (6 patients) for tirofiban
versus for placebo (odds ratio 1.82 [95% CI 0.67 to 4.95]).
A total of 4.2% (51) patients suffered a TIMI minor
hemorrhage (enoxaparin groups: 4.0% [24 patients], UFH
groups: 4.4% [27 patients]). Results for the four individual
groups are given in Table 6. A total of 194 patients (16.0%)
suffered any hemorrhage (enoxaparin groups: 17.8% [107
patients], UFH groups: 14.1% [87 patients]). The incidence
of any hemorrhage was significantly higher in the pooled
tirofiban versus placebo groups (18.9% [116 patients] in
tirofiban group versus 12.9% [78 patients] in placebo group,
p value  0.005), with the highest incidence seen in the
enoxaparin/tirofiban group (20.1%), Table 6. Eight patients
suffered a stroke by the 30-day assessment (four in the
enoxaparin groups and four in the UFH groups). The safety
profiles were similar across the treatment groups with no
notable differences detected. The most common “non-
bleeding” adverse event was heart failure (7.0%), followed by
chest pain (5.4%) and hypotension (4.8%). A total of 14.7%
of patients had a serious adverse event, with rates again
being similar between groups (15.7% in pooled enoxaparin
groups and 13.8% in pooled UFH groups).
DISCUSSION
The TETAMI study is the first large, randomized, non-
lytic, antithrombotic trial to focus on the significant fraction
Table 4. Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days for Pooled
Tirofiban and Placebo Groups (Intention-to-Treat Population, N  1,224)
Tirofiban
(n  619)
Placebo
(n  605)
Odds Ratio
(95% CI)
Primary efficacy outcome (triple end point) 103 (16.6%) 99 (16.4%) 1.02 (0.75–1.38)
Secondary efficacy outcome (double end point) 51 (8.2%) 54 (8.9%) 0.92 (0.61–1.37)
Any death 38 (6.1%) 45 (7.4%)
Any MI 20 (3.2%) 13 (2.1%)
Any recurrent angina 59 (9.5%) 49 (8.1%)
At least one revascularization 163 (26.3%) 181 (29.9%)
At least one PCI 129 (20.8%) 135 (22.3%)
At least one PCI on treatment 38 (6.1%) 11 (1.8%)
At least one CABG 35 (5.7%) 46 (7.6%)
CABG  coronary artery bypass grafting; CI  confidence interval; MI  myocardial infarction; PCI  percutaneous coronary
intervention.
Table 3. Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days for Pooled
Enoxaparin and UFH Groups (Intention-to-Treat Population, N  1,224)
All Patients
(N  1,224)
Enoxaparin
(n  604)
UFH
(n  620)
Odds Ratio
(95% CI)
Primary efficacy outcome
(triple end point)
202 (16.5%) 95 (15.7%) 107 (17.3%) 0.89 (0.66–1.21)
Secondary efficacy outcome
(double end point)
105 (8.6%) 52 (8.6%) 53 (8.5%) 1.01 (0.68–1.50)
Any death 83 (6.8%) 42 (7.0%) 41 (6.6%)
Any MI 33 (2.7%) 15 (2.5%) 18 (2.9%)
Any recurrent angina 108 (8.8%) 49 (8.1%) 59 (9.5%)
At least one revascularization 344 (28.1%) 157 (26.0%) 187 (30.2%)
At least one PCI 264 (21.6%) 116 (19.2%) 148 (23.4%)
At least one PCI on treatment 27 (2.2%) 12 (2.0%) 15 (2.4%)
At least one CABG 81 (6.6%) 41 (6.8%) 40 (6.5%)
CABG  coronary artery bypass grafting; CI  confidence interval; MI  myocardial infarction; PCI  percutaneous coronary
intervention; UFH  unfractionated heparin.
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of patients with STEMI who do not receive reperfusion
therapies. The benefits of early coronary artery reperfusion
using fibrinolytics or PCI for patients with STEMI have
been well established, but typically the majority of large
clinical trials investigating STEMI treatments only include
patients who present within 12 h of symptom onset.
However, around 30% of eligible patients do not receive
appropriate reperfusion therapy, and there are no current
standard treatment guidelines for this patient group (2,3).
The reasons for not receiving reperfusion include presenta-
tion later than 12 h from symptom onset; geographic
variations in practice patterns (25); and patient race (6),
gender (26,27), and age (5). Elderly patients (65 years)
constitute half of hospital admissions for STEMI and as
many as 80% of STEMI deaths (28). An analysis of 163,140
elderly Medicare patients revealed that, although mortality
after STEMI increased rapidly with age, use of evidence-
based therapies (beta-blockers, aspirin, reperfusion) de-
creased with increasing age (28). Ironically, other high-risk
subgroups, such as patients presenting with STEMI and
congestive heart failure (29) or previous CABG, are also
particularly unlikely to receive reperfusion therapy.
Although the benefits of early reperfusion have been
established, the role of late reperfusion remains controver-
sial; significantly reduced rates of clinical events and bene-
ficial effects on left ventricular function have been shown
after late PCI (9). Zahn et al. (30) found that, while a
pre-hospital delay of more than 12 h prevented any bene-
ficial effect of thrombolysis, primary angioplasty did show
beneficial effects in such cases. Multiple logistic regression
showed only trends for both end points. A retrospective
analysis demonstrated that an initial invasive approach may
be more beneficial than medical therapy alone in patients
presenting with chest pain after 12 h and STEMI (31).
However, physician bias appears to divert the sicker patients
preferentially to medical therapy rather than to initial
invasive therapy. In contrast, lower risk patients were more
commonly given invasive therapy rather than medical ther-
Figure 2. Time to first event (death or adjudicated MI or adjudicated recurrent angina) at 30 days (enoxaparin vs. unfractionated heparin [UFH])
(intention-to-treat population, N  1,224). Censor: marks point at which patients were withdrawn from study without further 30-day follow-up data.
Table 5. Summary of Efficacy Results: Adjudicated Clinical End Points at 30 Days (Intention-to-Treat Population, N  1,224)
All Patients
(N  1,224)
Enoxaparin/Placebo
(n  299)
Enoxaparin/Tirofiban
(n  305)
UFH/Placebo
(n  306)
UFH/Tirofiban
(n  314)
p Value for
Treatment
Interaction
Primary efficacy outcome
(triple end point)
202 (16.5%) 46 (15.4%) 49 (16.1%) 53 (17.3%) 54 (17.2%) 0.846
Secondary efficacy outcome
(double end point)
105 (8.6%) 26 (8.7%) 26 (8.5%) 28 (9.2%) 25 (8.0%)
Any death 83 (6.8%) 22 (7.4%) 20 (6.6%) 23 (7.5%) 18 (5.7%)
Any MI 33 (2.7%) 5 (1.7%) 10 (3.3%) 8 (2.6%) 10 (3.2%)
Any recurrent angina 108 (8.8%) 22 (7.4%) 27 (8.9%) 27 (8.8%) 32 (10.2%)
MI  myocardial infarction; UFH  unfractionated heparin.
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apy. Another retrospective analysis by Srinivas et al. (32)
demonstrated no difference between outcomes with early
(within 6 h) and delayed (6 to 23 h) angioplasty. The most
recent prospective, randomized trial, the Open Artery Trial
(TOAT), demonstrated that late PCI after transmural
anterior MI is feasible and leads to improved quality of life
and exercise tolerance, but is associated with significantly
greater left ventricular dilation than a non-invasive strategy
(10).
The TETAMI study was designed to compare the
efficacy and safety of non-lytic antithrombotic therapy using
enoxaparin versus UFH, in combination with tirofiban or
placebo, in an attempt to enhance late reperfusion of the
infarct-related artery and/or prevent thrombotic re-
occlusion of the infarct-related artery in patients with
STEMI presenting too late for traditional reperfusion.
However, the results of this study did not show that
enoxaparin given for 2 to 8 days to STEMI patients
significantly reduced the 30-day composite end point of
death, reinfarction, and recurrent angina when compared
with UFH. Enoxaparin was observed to have a similar safety
and efficacy profile to UFH and may be an alternative to
UFH in non-reperfused STEMI patients. The addition of
tirofiban in combination with enoxaparin or UFH did not
show a benefit in this patient population.
A closer look at the treatment effects suggests that none
of the antithrombotic regimens tested appear to have a
differential effect on mortality. This would be in keeping
with the previously described lackluster effects of late PCI
(10,30,31). However, the TETAMI data suggest a wider,
although not significant, benefit of enoxaparin on the
individual outcomes of MI and recurrent angina. Unlike
death, which is overwhelmingly determined by left ventric-
ular function at admission, both MI and recurrent angina
are predominantly due to recurrent thrombotic events.
Reinfarction, in which there is a small trend for reduction
with enoxaparin in this study, is sometimes described as a
“soft” end point, with “harder” end points such as death
being considered more reliable indicators of clinical efficacy.
However, studies investigating the incidence of reinfarction
after fibrinolysis indicate that patients with reinfarction have
significantly higher rates of long-term mortality and heart
failure than patients without recurrent ischemic events
(33,34). Hudson et al. (34) found that the unadjusted
mortality rate was 3 higher at 30 days and 1.5 higher from
30 days to 1 year in patients with early reinfarction versus
those without reinfarction, with most patients dying soon
after the event, and 40% of all deaths occurring within 24 h.
With reinfarction being a predictor of long-term mortality,
early revascularization and prevention of reinfarction
should, therefore, be a key goal of STEMI management.
Study limitations. Several aspects of this study may have
confounded the results. First, in retrospect, it appears that
the study was underpowered to detect a significant differ-
ence given the event rates observed, and a 30% relative
reduction in events was perhaps too optimistic. It took 3
years to recruit 1,224 patients into this study, and overall
mortality from MI appears to be steadily decreasing over
time (35). Even so, the overall mortality rate observed of 7%
is much lower than expected, and the low event rate
contributes to the reduced power of the study. Second, 28%
of all randomized patients had already received an anti-
thrombotic therapy, namely intravenous UFH, before ran-
domization (therefore, polluting the treatment group for
enoxaparin patients having received UFH bolus rather than
enoxaparin bolus). Third, the study was not designed to
assess the effect of treatment in patients presenting earlier in
their post-infarction course. Both enoxaparin and tirofiban
have been shown to provide benefit in acute coronary
syndromes when administered early. It is possible that a
benefit of treatment might have been achieved in patients
presenting within 12 h but in whom reperfusion was
contraindicated for other reasons. In addition, a relatively
small number of patients went on to undergo PCI in this
study, and it has been observed that glycoprotein IIb/IIIa
inhibitors have a greater effect in patients undergoing PCI.
Furthermore, the bolus dose of tirofiban utilized in this
study could have been too low to give a meaningful level of
platelet inhibition (36). Future trials with more statistical
power and including much larger numbers of patients may
provide the possibility of detecting treatment benefits in this
important group of patients, which urgently need optimal
treatment regimens to be defined.
Conclusions. The TETAMI study did not achieve its
primary aim, and the newer antithrombotic regimens were
not significantly different from the traditional regimen of
UFH with regard to the composite triple end point of death,
reinfarction, and recurrent angina, and especially death,
following STEMI.
Acknowledgments
The authors thank Susan Slatylak and Peter M. DiBattiste
for their support in developing and conducting this trial
in its early phase. The authors would also like to thank
Table 6. Hemorrhage Rates at 30 Days (All Treated Population, N  1,216)
All Patients
(N  1,216)
Enoxaparin/Placebo
(n  297)
Enoxaparin/Tirofiban
(n  303)
UFH/Placebo
(n  306)
UFH/Tirofiban
(n  310)
TIMI major hemorrhage 17 (1.4%) 3 (1.0%) 6 (2.0%) 3 (1.0%) 5 (1.6%)
TIMI minor hemorrhage 51 (4.2%) 12 (4.0%) 12 (4.0%) 8 (2.6%) 19 (6.1%)
TIMI “loss no site” 39 (3.2%) 11 (3.7%) 14 (4.6%) 6 (2.0%) 8 (2.6%)
Any hemorrhage 194 (16.0%) 46 (15.5%) 61 (20.1%) 32 (10.5%) 55 (17.7%)
TIMI  Thrombolysis In Myocardial Infarction; UFH  unfractionated heparin.
1354 Cohen et al. JACC Vol. 42, No. 8, 2003
Results of the TETAMI Trial October 15, 2003:1348–56
Dr. Jacqueline Mason for her assistance in the preparation
of this manuscript.
Reprint requests and correspondence: Dr. Marc Cohen, Cardiac
Catheterization Laboratory, Newark Beth Israel Medical Center,
Newark, New Jersey 07112. E-mail: marcohen@sbhcs.com.
REFERENCES
1. The American Heart Association. Heart and Stroke Facts: Statistical
Supplement. Dallas, TX; The American Heart Association, 2003.
2. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute
myocardial infarction in patients presenting with ST-segment eleva-
tion. Eur Heart J 2003;24:28–66.
3. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA
guidelines for the management of patients with acute myocardial
infarction. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee on
Management of Acute Myocardial Infarction). J Am Coll Cardiol
1999;3:890–911.
4. Rogers WJ, Canto JG, Lambrew CT, et al., for the Investigators in the
National Registry of Myocardial Infarction 1, 2 and 3. Temporal
trends in the treatment of over 1.5 million patients with myocardial
infarction in the U.S. from 1990 through 1999: the National Registry
of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056–
68.
5. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM,
Lopez-Sendon J. Practice variation and missed opportunities for
reperfusion in ST-segment-elevation myocardial infarction: findings
from the Global Registry of Acute Coronary Events (GRACE).
Lancet 2002;359:373–7.
6. Barron HV, Bowlby LJ, Breen T, et al. Use of reperfusion therapy for
acute myocardial infarction in the United States: data from the
National Registry of myocardial infarction 2. Circulation 1998;97:
1150–6.
7. LATE Study Group. Late Assessment of Thrombolytic Efficacy
(LATE) study with alteplase 6–24 hours after onset of acute myocar-
dial infarction. Lancet 1993;342:759–66.
8. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de
America del Sur) Collaborative Group. Randomized trial of late
thrombolysis in patients with suspected acute myocardial infarction.
Lancet 1993;342:767–72.
9. Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of
late reperfusion for acute anterior myocardial infarction with percuta-
neous transluminal coronary angioplasty. Circulation 1998;98:2377–
82.
10. Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late
intervention after anterior myocardial infarction: effects on left ven-
tricular size, function, quality of life, and exercise tolerance: results of
The Open Artery Trial (TOAT study). J Am Coll Cardiol 2002;40:
869–76.
11. Ottesen MM, Køber L, Jørgensen S, Torp-Pedersen C, on behalf of
the TRACE Study Group. Consequences of overutilization and
underutilization of thrombolytic therapy in clinical practice. J Am Coll
Cardiol 2001;37:1581–7.
12. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents
death and cardiac ischemic events in unstable angina/non–Q-wave
myocardial infarction: results of the Thrombolysis In Myocardial
Infarction (TIMI) 11B trial. Circulation 1999;100:1593–601.
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-
molecular-weight heparin with unfractionated heparin for unstable
coronary artery disease: Efficacy and Safety of Subcutaneous Enoxapa-
rin in Non–Q-wave Coronary Events Study Group. N Engl J Med
1997;337:447–52.
14. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in
combination with enoxaparin, abciximab or unfractionated heparin:
the ASSENT-3 randomized trial in acute myocardial infarction.
Lancet 2001;358:605–13.
15. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison
of enoxaparin, a low-molecular-weight heparin, with unfractionated
heparin adjunctive to recombinant tissue plasminogen activator throm-
bolysis and aspirin: second trial of Heparin and Aspirin Reperfusion
Therapy (HART II). Circulation 2001;104:648–52.
16. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as
adjunctive antithrombin therapy for ST-elevation myocardial infarc-
tion: results of the ENTIRE-Thrombolysis In Myocardial Infarction
(TIMI) 23 trial. Circulation 2002;105:1642–9.
17. The Platelet Receptor inhibition in Ischemic Syndrome Management
in Patients Limited by Unstable signs and Symptoms (PRISM-PLUS)
Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa
receptor with tirofiban in unstable angina and non–Q-wave myocardial
infarction. N Engl J Med 1998;338:1488–97.
18. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
N Engl J Med 1998;339:436–43.
19. PRISM Study Investigators. A comparison of aspirin plus tirofiban
with aspirin plus heparin for unstable angina: Platelet Receptor
Inhibition in Ischemic Syndrome Management (PRISM) Study In-
vestigators. N Engl J Med 1998;338:1498–505.
20. Cohen M, Theroux P, Weber S, et al. Combination therapy in
tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol
1999;71:273–81.
21. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind
safety study of enoxaparin versus unfractionated heparin in patients
with non–ST-segment elevation acute coronary syndromes treated
with tirofiban and aspirin: the ACUTE II study: the Antithrombotic
Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:
470–7.
22. Cohen M, Maritz F, Gensini GF, et al. The TETAMI trial: the safety
and efficacy of subcutaneous enoxaparin versus intravenous unfraction-
ated heparin and of tirofiban versus placebo in the treatment of acute
myocardial infarction for patients not thrombolyzed: methods and
design. J Thromb Thrombolysis 2000;10:241–6.
23. Cohen M, Antman EM, Gurfinkel E, et al. Impact of enoxaparin low
molecular weight heparin in patients with Q-wave myocardial infarc-
tion: a subgroup meta-analysis from the TIMI 11B and ESSENCE
trials. Am J Cardiol 2000;86:553–6.
24. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa
blockade with tirofiban on adverse cardiac events in patients with
unstable angina or acute myocardial infarction undergoing coronary
angioplasty: randomized efficacy study of tirofiban for outcomes and
restenosis. Circulation 1997;96:1445–53.
25. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United
States in the management of acute myocardial infarction. N Engl
J Med 1995;333:565–72.
26. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM.
Sex-based differences in early mortality after myocardial infarction.
N Engl J Med 1999;341:217–25.
27. MacIntyre K, Stewart S, Capewell S, et al. Gender and survival: a
population-based study of 201,114 men and women following a first
acute myocardial infarction. J Am Coll Cardiol 2001;38:729–35.
28. Mehta RH, Rathore SS, Radford MJ, Wang Y, Wang Y, Krumholz
M. Acute myocardial infarction in the elderly: differences by age. J Am
Coll Cardiol 2001;38:736–41.
29. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in
patients presenting with congestive heart failure complicating acute
myocardial infarction. J Am Coll Cardiol 2002;40:1389–94.
30. Zahn R, Schiele R, Schneider S, et al. Primary angioplasty versus no
reperfusion therapy in patients with acute myocardial infarction and a
pre-hospital delay of 12–24 hours: results from the pooled data of
the maximal individual therapy in acute myocardial infarction (MI-
TRA) registry and the Myocardial Infarction Registry (MIR). J Inva-
sive Cardiol 2001;13:367–72.
31. Elad Y, French WJ, Shavelle DM, Parsons LS, Sada MJ, Every NR.
Primary angioplasty and selection bias in patients presenting late
(12h) after onset of chest pain and ST elevation myocardial infarc-
tion. J Am Coll Cardiol 2002;39:826–33.
32. Srinivas VS, Vakili BA, Brown DL. Comparison of in-hospital
outcomes following early or delayed angioplasty for acute myocardial
infarction. J Invasive Cardiol 2002;14:746–50.
33. Bahit MC, Topol EJ, Califf RM, et al. Reactivation of ischemic events
in acute coronary syndromes: results from GUSTO-IIb. J Am Coll
Cardiol 2001;37:1001–7.
34. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after
1355JACC Vol. 42, No. 8, 2003 Cohen et al.
October 15, 2003:1348–56 Results of the TETAMI Trial
fibrinolysis: experience from the Global Utilization of Streptokinase
and Tissue plasminogen activator (alteplase) for Occluded coronary
arteries (GUSTO I) and global use of strategies to open occluded
coronary arteries (GUSTO III) trials. Circulation 2001;104:1229–35.
35. Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year
(1975 to 1997) trends in the incidence, in-hospital and long-term case
fatality rates from initial Q-wave and non–Q-wave myocardial infarc-
tion: a multi-hospital, community-wide perspective. J Am Coll Car-
diol 2001;37:1571–80.
36. Herrmann HC, Swierkosz TA, Kapoor S, et al. Comparison of degree
of platelet inhibition by abciximab versus tirofiban in patients with
unstable angina pectoris and non–Q-wave myocardial infarction un-
dergoing percutaneous coronary intervention. Am J Cardiol 2002;89:
1293–7.
APPENDIX
Steering Committee: M. Cohen, U.S. (Study Chairman); G.
Gensini, Italy; E. Gurfinkel, Argentina; F. Maritz, South
Africa; K. Huber, Austria; M. Krzeminska-Pakula, Poland;
A. Timerman, Brazil; N. Danchin, France; H. White, New
Zealand; K. A. Fox, UK.
Data Safety Monitoring Board: A. Leizorovicz (Chair);
J. Chesebro; M. Flather; M. Kern.
Clinical Events Committee: J. Ambrose; N. Kleiman; J.
Zidar.
1356 Cohen et al. JACC Vol. 42, No. 8, 2003
Results of the TETAMI Trial October 15, 2003:1348–56
